At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you
GPs should be looking at the effectiveness of the medicines they prescribe INCLUDING the cost effectiveness since money saved is money available for further care
